Applied Filters
Allergan and tribe hit back at Mylan claims in SCOTUS brief
Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
Teva enters settlement with Novo Nordisk to sell Victoza generic
Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
WHO and UN actions undermine IP and hurt innovation, warns PhRMA
Supranational organisations such as the World Health Organization and the United Nations Development Program are promoting acts, policies and practices that prevent biopharmaceutical innovators from securing and maintaining patents.
National Cancer Institute’s director named as acting FDA chief
The Trump administration has named Ned Sharpless, director of the National Cancer Institute, as the Food and Drug Administration's (FDA) acting commissioner.
FDA chief Gottlieb resigns after nearly two years
Scott Gottlieb, commissioner of the US Food and Drug Administration, resigned from his post yesterday, March 5, with plans to step down in the next month.
UK court overturns Genentech patent, cites Brexit in CJEU referral
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
US FTC settles pay-for-delay case with AbbVie
The US Federal Trade Commission concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
Amgen prevails against Sanofi and Regeneron
A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Indivior to launch generic after SCOTUS refuses petition
Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.
Teva and FTC reach settlement over ‘pay-for-delay’
Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
